Iliac Artery DiseaseNCT07012551
Endovascular Modalites for Contralateral Common Iliac Artery in Patients With Symptomatic Unilateral Common Iliac Artery Occlusive Disease
An observational study of Iliac Artery Disease, run by Assiut University.
Trial summary
To evaluate the safety, efficacy, and outcomes of endovascular strategies for protection of the contralateral CIA in patients with symptomatic unilateral CIA occlusive disease Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Iliac Artery Disease
- What is being tested?
- Common iliac artery stenting
- Type of treatment
- Surgery or procedure
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 1 May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients attending the Vascular Surgery Clinics in Assiut University Hospitals complaining of unilateral CIA ostial occlusive disease, Rutherford category 3, 4and 5 will be recruited to participate in the study.
Who may be able to join
- Symptomatic patients (Rutherford category 3- 5) due to Unilateral common iliac artery occlusive disease.
- with or without combined iliac or femoropopliteal or infrapopliteal lesions.
- Asymptomatic Contralateral limb.
- Patent at least one run-off vessel
Who cannot join
- Distal aorta lesion
- contralateral CIA occlusion
- Previous endovascular or surgical procedures for the same lesion
- Hypersensitivity to contrast material
- Presence of aortic or iliac aneurysms
- Patients with unsalvageable limb
- Non atherosclerotic lesions
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
To evaluate the safety, efficacy, and outcomes of endovascular strategies for protection of the contralateral CIA in patients with symptomatic unilateral CIA occlusive disease
- Conditions
- Iliac Artery Disease
- Being tested
- Common iliac artery stenting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Common iliac artery stentingProcedure or surgery
Stenting of common iliac artery by balloon mounted stent
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary patency of both common iliac arteries
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2025
- Study start1 Aug 2025 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Iliac Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abdelrahman Ahmed Shawki Roshdi, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07012551
- Sponsor's protocol ID
- Common iliac artery stenting
- Status last verified
- Jun 2025
- First submitted
- 1 Jun 2025
- Last updated
- 10 Jun 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010 Mar 2;55(9):898-903. doi: 10.1016/j.jacc.2009.09.055.
PubMed 20185041
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Endovascular Modalites for Contralateral Common Iliac Artery in Patients With Symptomatic Unilateral Common Iliac Artery Occlusive Disease
- ClinicalTrials.gov ID
- NCT07012551
- Acronym / sponsor ID
- Common iliac artery stenting
- Conditions
- Iliac Artery Disease
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 10 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the safety, efficacy, and outcomes of endovascular strategies for protection of the contralateral CIA in patients with symptomatic unilateral CIA occlusive disease
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients attending the Vascular Surgery Clinics in Assiut University Hospitals complaining of unilateral CIA ostial occlusive disease, Rutherford category 3, 4and 5 will be recruited to participate in the study.
Key inclusion criteria (4 listed)
- Symptomatic patients (Rutherford category 3- 5) due to Unilateral common iliac artery occlusive disease.
- with or without combined iliac or femoropopliteal or infrapopliteal lesions.
- Asymptomatic Contralateral limb.
- Patent at least one run-off vessel
Key exclusion criteria (7 listed)
- Distal aorta lesion
- contralateral CIA occlusion
- Previous endovascular or surgical procedures for the same lesion
- Hypersensitivity to contrast material
- Presence of aortic or iliac aneurysms
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Common iliac artery stentingStenting of common iliac artery by balloon mounted stent | Procedure or surgery | – |
Primary outcome
Primary patency of both common iliac arteries
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2025.
- Background: PubMed 20185041Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010 Mar 2;55(9):898-903. doi: 10.1016/j.jacc.2009.09.055.
- Individual participant dataSharing planned: No
Related trials for Iliac Artery Disease
Active, not recruitingObservational study
External Iliac Artery Endofibrosis in Cycling
Iliac Artery Occlusive Disease, Blood Flow Velocity
Active, not recruitingObservational study
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
Peripheral Artery Disease, Popliteal Aneurysm
Recruiting
iHub Stent-Graft for Iliac Artery Aneurysms: Safety, Performance, and Effectiveness Study
Iliac Aneurysm, Aortic Aneurysm, Abdominal
RecruitingObservational study
Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study
Peripheral Arterial Disease, Aortoiliac Occlusive Disease
RecruitingObservational study
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Post-Market Clinical Follow-Up (PMCF) Observational Registry (RE-PROVE)
Aorto-iliac Occlusive Disease (AIOD), Visceral Artery Occlusive Disease (VAOD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Iliac Artery Disease, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact abdelrahman eltokhey (01003830585, abdelrahmaneltokhey11@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary patency of both common iliac arteries (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07012551, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2025.